Cargando…

Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease

Hyperkalemia (serum potassium [K+] ≥5.1) is life-threatening in patients diagnosed with end stage kidney disease (ESKD). Patiromer is approved for the treatment of hyperkalemia, although its role in hyperkalemic patients with ESKD is not well understood. This study describes real-world patiromer uti...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinnell, Derek, Patel, Shardool, Qualls, Joshua, Chen, Wei, Rathod, Anitha, Woods, Steven D., Boutin, Sylvie, Kovesdy, Csaba P., Tangri, Navdeep, Sauer, Brian C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771256/
https://www.ncbi.nlm.nih.gov/pubmed/36550897
http://dx.doi.org/10.1097/MD.0000000000032367
_version_ 1784854783456182272
author Pinnell, Derek
Patel, Shardool
Qualls, Joshua
Chen, Wei
Rathod, Anitha
Woods, Steven D.
Boutin, Sylvie
Kovesdy, Csaba P.
Tangri, Navdeep
Sauer, Brian C.
author_facet Pinnell, Derek
Patel, Shardool
Qualls, Joshua
Chen, Wei
Rathod, Anitha
Woods, Steven D.
Boutin, Sylvie
Kovesdy, Csaba P.
Tangri, Navdeep
Sauer, Brian C.
author_sort Pinnell, Derek
collection PubMed
description Hyperkalemia (serum potassium [K+] ≥5.1) is life-threatening in patients diagnosed with end stage kidney disease (ESKD). Patiromer is approved for the treatment of hyperkalemia, although its role in hyperkalemic patients with ESKD is not well understood. This study describes real-world patiromer utilization in an ESKD population and its corresponding association with serum K+ level changes. The study population was comprised of US veterans with an outpatient dispensing of patiromer and 2 or more International Classification of Diseases diagnostic codes for ESKD. A treatment course of patiromer was defined by serial dispensing events without a 30-day gap. Patiromer utilization was described by duration, average dose, persistence, and proportion of days covered during patiromer course. Mean serum K+ values were described for baseline and 3 follow-up intervals during the 180-day follow-up period. There were 458 patients with ESKD included in the study. On average, patients had 1.24 (95% CI: 1.20–1.29) patiromer courses. Half of the population discontinued their first patiromer course within 30 days, while approximately 10% of patients remained persistent at the end of the 180-day period and 102 (22.3%) patients started a second course during the 180-day follow up period. Average serum K+ concentrations during baseline and the 3 evaluation intervals during the 180-day follow-up were 5.91 mEq/L (5.85–5.97), 4.94 mEq/L (4.86–5.03), 4.89 mEq/L (4.8–4.98) and 4.88 mEq/L (4.8–4.96). Few patients remained persistent on their initial course of patiromer at the end of follow-up, but approximately 20% of patients initiated a second treatment episode after a 30-day gap in treatment during the 180-day follow-up period. Nonetheless, average serum K+ in ESKD patients were sustainably reduced by approximately 1 mEq/L during follow-up.
format Online
Article
Text
id pubmed-9771256
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97712562022-12-22 Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease Pinnell, Derek Patel, Shardool Qualls, Joshua Chen, Wei Rathod, Anitha Woods, Steven D. Boutin, Sylvie Kovesdy, Csaba P. Tangri, Navdeep Sauer, Brian C. Medicine (Baltimore) 5200 Hyperkalemia (serum potassium [K+] ≥5.1) is life-threatening in patients diagnosed with end stage kidney disease (ESKD). Patiromer is approved for the treatment of hyperkalemia, although its role in hyperkalemic patients with ESKD is not well understood. This study describes real-world patiromer utilization in an ESKD population and its corresponding association with serum K+ level changes. The study population was comprised of US veterans with an outpatient dispensing of patiromer and 2 or more International Classification of Diseases diagnostic codes for ESKD. A treatment course of patiromer was defined by serial dispensing events without a 30-day gap. Patiromer utilization was described by duration, average dose, persistence, and proportion of days covered during patiromer course. Mean serum K+ values were described for baseline and 3 follow-up intervals during the 180-day follow-up period. There were 458 patients with ESKD included in the study. On average, patients had 1.24 (95% CI: 1.20–1.29) patiromer courses. Half of the population discontinued their first patiromer course within 30 days, while approximately 10% of patients remained persistent at the end of the 180-day period and 102 (22.3%) patients started a second course during the 180-day follow up period. Average serum K+ concentrations during baseline and the 3 evaluation intervals during the 180-day follow-up were 5.91 mEq/L (5.85–5.97), 4.94 mEq/L (4.86–5.03), 4.89 mEq/L (4.8–4.98) and 4.88 mEq/L (4.8–4.96). Few patients remained persistent on their initial course of patiromer at the end of follow-up, but approximately 20% of patients initiated a second treatment episode after a 30-day gap in treatment during the 180-day follow-up period. Nonetheless, average serum K+ in ESKD patients were sustainably reduced by approximately 1 mEq/L during follow-up. Lippincott Williams & Wilkins 2022-12-16 /pmc/articles/PMC9771256/ /pubmed/36550897 http://dx.doi.org/10.1097/MD.0000000000032367 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 5200
Pinnell, Derek
Patel, Shardool
Qualls, Joshua
Chen, Wei
Rathod, Anitha
Woods, Steven D.
Boutin, Sylvie
Kovesdy, Csaba P.
Tangri, Navdeep
Sauer, Brian C.
Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
title Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
title_full Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
title_fullStr Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
title_full_unstemmed Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
title_short Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
title_sort real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
topic 5200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771256/
https://www.ncbi.nlm.nih.gov/pubmed/36550897
http://dx.doi.org/10.1097/MD.0000000000032367
work_keys_str_mv AT pinnellderek realworldevaluationofpatiromerutilizationanditseffectsonserumpotassiuminveteranswithendstagekidneydisease
AT patelshardool realworldevaluationofpatiromerutilizationanditseffectsonserumpotassiuminveteranswithendstagekidneydisease
AT quallsjoshua realworldevaluationofpatiromerutilizationanditseffectsonserumpotassiuminveteranswithendstagekidneydisease
AT chenwei realworldevaluationofpatiromerutilizationanditseffectsonserumpotassiuminveteranswithendstagekidneydisease
AT rathodanitha realworldevaluationofpatiromerutilizationanditseffectsonserumpotassiuminveteranswithendstagekidneydisease
AT woodsstevend realworldevaluationofpatiromerutilizationanditseffectsonserumpotassiuminveteranswithendstagekidneydisease
AT boutinsylvie realworldevaluationofpatiromerutilizationanditseffectsonserumpotassiuminveteranswithendstagekidneydisease
AT kovesdycsabap realworldevaluationofpatiromerutilizationanditseffectsonserumpotassiuminveteranswithendstagekidneydisease
AT tangrinavdeep realworldevaluationofpatiromerutilizationanditseffectsonserumpotassiuminveteranswithendstagekidneydisease
AT sauerbrianc realworldevaluationofpatiromerutilizationanditseffectsonserumpotassiuminveteranswithendstagekidneydisease